The major driving factor for emphysema treatment in global market is smoking habit of enormous population worldwide. As per survey smokers have six time more chances to suffer from emphysema compared to non-smokers.
New York, NY -- (SBWIRE) -- 02/10/2017 -- Chronic obstructive pulmonary disease (COPD) is kind of lung disease which happen due to chronic obstruction of lung airflow that interferes with normal breathing and is not fully reversible. One of the diseases that falls under the category of chronic obstructive pulmonary disease (COPD) is emphysema. Emphysema is also referred as obstructive disorder because inhalation and exhalation is slow down or even stop some time due to over inflammation of alveoli. According to the National Emphysema Foundation emphysema is characterized by injuries to the wall of lungs between air sacs. Emphysema can cause damage to air sac which results the change of shape of air sac or often destruction. This results the low gas exchanged in the lungs leading difficulty in breathing. The damage happen to thin membrane lining of air sacs is beyond repair which reduces flow of oxygen in the blood stream. This happens because air is trapped inside alveoli due to its damage results insufficient space for air to enter in the sacs. Emphysema have higher death due to respiratory failure, lung infection or heart attack. The emphysema patient can be treated by improving shortness in breath and reducing the number of hospitalization. Before treatment a pulmonary function test is performed to find how much air patient can blow.
The major driving factor for emphysema treatment in global market is smoking habit of enormous population worldwide. As per survey smokers have six time more chances to suffer from emphysema compared to non-smokers. Alpha-1 antitrypsin (AAT) deficiency is also another driving factor for emphysema but this has low cause compared to smokers. AAT deficiency is a form genetic disorder which results the damage of white blood cell on normal tissue in lungs. Approximately 2% to 3% of people suffering emphysema due to AAT deficiency. Treatment given to emphysema by inhale steroid method have some side effects such as weaken of bone and high risk of heart diseases. Treatment by oral steroid for emphysema may cause high blood pressure problem which my lead to heart diseases again.
A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/13690
The global market of emphysema treatment is segmented on the basis of treatment, disease indication, end users and geography.
Segmentation by Treatment
By Nicotine replacement products
By release of low levels of dopamine
Lung volume reduction surgery
Segmentation by Diseases Indication
Shortness of breath
Chronic mucus production
Thin and very pink skin
Segmentation by End User
Segmentation by Geography
Rest of the World
It is to be expected that the global market of emphysema treatment will show tremendous growth. According for the Centers for Disease Control and Prevention (CDC), people who are diagnosed with chronic lungs condition such as asthma or emphysema have high chances of flu virus. This causes respiratory problems which leads to inflammation and airway narrowing. The frequency of Chronic Obstructive Pulmonary Disorder (COPD) has shown in exponential growth in global market which has affected the wide range of health economy. Currently, smoking cessation have been preferred by most patient globally. Bronchodialators, corticosteroids, oxygen medications and other antibiotics such as erythromycin have huge demand in global market for treatment of emphysema. Pharmaceutical and medical industries have gained huge profit by generating new drugs for treatment of emphysema. High number of new product and therapies are entering the market which impose can impose the growth globally.
According to a survey 3.1 million adults in U.S. have suffered with emphysema due to cigarette smoking. The American Lung Association, COPD reports that emphysema is fourth leading cause death in U.S. Similarly World Health Organization (WHO) evaluate that around 210 people suffering from COPD worldwide. The WHO further states that these numbers will continue increasing under the influence of factors such as increase in proportion of urban population, changing life style, growing number of tobacco smokers and rising pollution level.
Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/13690
Some of the major key players for emphysema treatment market are Pulmonx Inc., Bioxyne Limited, Intrexon Corporation, Icure Pharmaceuticals, Inc. Kamada Limited and Emphasys Medical, Inc. Other prominent player in emphysema treatment market are Pfizer, Inc. Olympus Corporation, BTG International's, PneumRx and Uptake Medical Corporation.